AGEN
Agenus Inc.3.7200
+0.0100+0.27%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
126.51MP/E (TTM)
-Basic EPS (TTM)
-1.57Dividend Yield
0%Recent Filings
8-K
Agenus closes Zydus deal
Agenus closed its asset sale of Emeryville and Berkeley manufacturing facilities to Zydus on January 15, 2026, netting $75 million cash less expenses while securing committed U.S. capacity for BOT+BAL trials and commercialization. Zydus invested $16 million for 2.1 million AGEN shares at $7.50; exclusive BOT+BAL rights granted in India and Sri Lanka with 5% royalties to Agenus. Up to $50 million contingent milestones await. Deal bolsters cash, trims costs sharply.
8-K
Agenus names interim CFO
8-K
Ligand liens released, warrant repriced
10-Q
Q3 FY2025 results
Agenus swung to a Q3 profit with $30.2M revenue, up 20% y/y from $25.1M, driven by $29.1M non-cash royalty revenue (up 18% y/y) while R&D expenses plunged 43% to $23.6M and G&A fell 37% to $10.9M on lower headcount and deconsolidation of MiNK. Operating loss narrowed to $4.5M from $31.5M y/y, but net income of $63.9M reflected a $100.9M gain from MiNK deconsolidation in July 2025, offset by $19.3M non-operating expense and $13.2M interest; diluted EPS $1.94 reconciles to 32.9M shares. Cash dwindled to $3.5M amid $60.6M YTD operating burn, with $35.6M debt ($10.5M due June 2026); assets held for sale total $122.1M pending Q1 2026 Zydus close for $75M plus up to $50M contingent. Manufacturing facilities go. Litigation clouds botensilimab prospects.
8-K
BOT/BAL gains French access
Agenus reported Q3 2025 results on November 10, highlighting France's ANSM authorization for reimbursed compassionate access to BOT/BAL in refractory MSS mCRC patients, with treatment underway. ESMO data showed 42% two-year OS in 123 MSS mCRC cases and 39% across >400 pan-tumor patients. Phase 3 BATTMAN trial launches Q4 2025. Deconsolidation of MiNK yielded $100.9M gain.